90 results about "Molecular medicine" patented technology

The invention relates to the field of molecular medicine. In particular, it relates to compositions and methods to enhance the clearance of aberrant cells, e.g. cancer cells or virus-infected cells, by the host's immune system. Provided is a composition comprising (i) a therapeutic compound that can trigger a host's immune effector cells against an aberrant cell, such as a therapeutic antibody, and (ii) at least one agent capable of reducing or preventing inhibitory signal transduction initiated via SIRPalpha.

The disclosure relates to metallic nanophotonic crescent structures, or “nanocrescent SERS probes,” that enhance detectable signals to facilitate molecular detections. More particularly, the nanocrescent SERS probes of the disclosure possess specialized geometries, including an edge surrounding the opening that is capable of enhancing local electromagnetic fields. Nanosystems utilizing such structures are particularly useful in the medical field for detecting rare molecular targets, biomolecular cellular imaging, and in molecular medicine.

The temperature sensitive hydro gel medicine releasing system and its preparation process belongs to the field of medicine technology. The medicine releasing system consists of carried medicine 0.1-30 wt%, temperature sensitive hydro gel 20-90 wt%, and high molecular weight polysaccharide 5-50 wt%. The medicine releasing system is prepared through a polysaccharide-temperature sensitive hydro gel compounding process, a polysaccharide-temperature sensitive hydro gel hydrophilic emulsifying process or a polysaccharide-temperature sensitive hydro gel emulsifying process. Owing to the retarding diffusion effect during solution-gel conversion, the present invention has raised medicine carrying amount, and improved medicine stability. The present invention provides simple and practical technological scheme for the controllable conveyance of biological macro molecular medicine and other treating components and the improvement of carried medicine release.

A multi-arm tree fork type polyethanediol with active terminal group is disclosed, and can be used to modify the low-molecular medicines, and protein or polypeptide medicines for improving their solubility, stability and immunogenicity, resulting in elongated half life period and raised curative effect.

The invention relates to the molecular medicine and gene treating field, in particularly, a gene segment which is new, cell target special, and can eliminate replication ability and synthesizing ability of nucleocapsid protein from source and clean the pollution protein. The gene segment is composed of a recombinant aden-associated virus vector helper plasmid non-structure and/or structure gene, and at least one copy cell special microRNA target sequence which can be used in multiple cell strains directly, and also can be used for constructing recombinant aden-associated virus plasmid and vector to prepare medicine, basic medicine and clinic gene treating.

The invention relates to the field of molecular medicine, and in particular relates to a gene chip for leukemia diagnosis and treatment. The chip contains oligonucleotide probes with sequences in SEQ ID NO:1-137. The chip has the following beneficial effects that: the actual demands in the blood system tumor diagnosis and treatment process in China are met; the gene chip is customized by screening key indicators in examination indicators in leukemia morphology, immunology, cytogenetics and molecular biology; and the multifunctional gene chip integrates early diagnosis, early warning, prevention and diagnosis and treatment of leukemia and can improve the individual diagnosis efficiency and treatment effect of leukemia, shorten the length of stay, reduce the medical expenses and improve the technical levels of the primary-level medical and health institutions.

The present invention provides a technology and a method for preparing a high-throughput exfoliated cell chip. According to the present invention, a cervix brush is adopted to collect cervix exfoliated cells of 26 cervical lesions patients and are immediately placed into a cell preservation solution, centrifugation is performed, the supernatant is removed, a cell immobilization solution is added to immobilize cell precipitate, dehydration transparency and dipping in wax are performed, a tissue chip instrument is adopted to prepare an exfoliated cell paraffin chip and an exfoliated cell paraffin block array, and paraffin slicing is performed to prepare the exfoliated cell chip; and the defect of the conventional cytology detection is overcome, and the prepared exfoliated cell chip can be used for pathological diagnosis, IHC, in situ hybridization and other molecular medicine researches.

The invention provides a technology and method for preparing high throughput needle biopsy tissue chip. The method comprises the following steps: collecting 42 residual paraffin-embedded tissue samples of needle biopsy of patients who have been diagnosed as the breast cancer patients through pathological examination on mammary gland needle biopsy tissues; taking the corresponding normal pathological HE stained sections as the guide, cutting the paraffin-embedded tissue sections (1mm to 4mm) corresponding to the cancer parts of the HE-stained sections, preparing paraffin-embedded tissue cores, preparing breast cancer needle biopsy tissue arrays by utilizing a tissue chip instrument, cutting paraffin into slices, and preparing paraffin-embedded tissue chip of breast cancer needle biopsy tissue. The prepared needle biopsy tissue chip can be applied to molecular medical research of related diseases such as immunocytochemistry, in-situ hybridization, and the like.

The invention relates to the field of molecular medicine and pharmacology. More specifically, it relates to liposomes and their use as delivery vehicle for therapeutic compounds. Provided is a liposome comprising at least one lipid bilayer enclosing an interior compartment, wherein said lipid bilayer comprises at least one synthetic pyridinium-derived amphiphile, for instance a Saint-molecule.

The invention provides a nanocomposite of DNA tetrahedron and microRNA, and belongs to the field of nucleic acid molecular medicine. The nanocomposite of the invention is composed of microRNA and a DNA tetrahedron; the DNA tetrahedron is a tetrahedral structure formed by base pairing of four DNA single strands; and the microRNA is covalently linked to a single strand of the DNA tetrahedron. The nanocomposite of the invention has strong stability and high cell entry efficiency, can be developed into various microRNA-related drugs, and has a good application prospect.

The present invention concerns the fields of molecular medicine and targeted delivery of therapeutic agents. More specifically, the present invention relates to the identification of novel peptide sequences that incorporate the amino acids Leu-Pro-Arg (LPR), and particularly _D(LPR), that selectively target VEGFR-I and NRP-I expressing cells. Targeted molecules in accor-dance with the invention are useful in the treatment and detection of neovascular or angiogenic VEGF associated disorders, including but not limited to cancer, obesity, diabetes, asthma, arthritis, cirrhosis and ocular diseases.

The invention relates to the field of molecular pharmaceutics and molecular medicine, in particular to a CD4 positive cell specific gene transfer vector and application thereof. The invention providesthe CD4 positive cell specific gene transfer vector. The transfer vector is a recombinant adeno-associated virus with a heptapeptide inserted into capsid protein of the recombinant adeno-associated virus (rAAV); and the amino acid sequence of the heptapeptide is shown as any one of SED ID NO: 1-26. According to the transfer vector, after the heptapeptide is inserted into the capsid protein of therAAV, the rAAV can efficiently deliver a transgenic element to a CD4 positive cell in a targeted mode. The transfer vector can selectively transduce the CD4 positive cell, the transgenic expression level is obviously higher than that of a wild rAAV2 vector, and effective targeted gene editing can be carried out.

The invention provides a photoresponse-nitric oxide donor molecule and derivatives and a preparing method thereof. The photoresponse-nitric oxide donor molecule of the structure shown in the formula (I) can make a sensitive response under the low radiation intensity by selecting a proper structure, a high-molecular prodrug can be further prepared, self-assembling is further conducted, a high-molecular medicine good in performance is obtained, and the toxicity is reduced compared with an existing photoresponse-nitric oxide donor molecule.

The invention provides a heteropolyacid nano-molecular medicine as well as a preparation method and an application thereof. The medicine comprises heteropolyacid or heteropolyacid salt molecules and a coating material coating the surface of heteropolyacid or the heteropolyacid salt molecules, wherein the heteropolyacid or heteropolyacid salt molecules have the structure shown in (I), (II) or (III). The heteropolyacid nano-molecular medicine can selectively interact with tumor cells and can be used as a contrast agent in magnetic resonance imaging and CT diagnosis of tumors; besides, the medicine molecules have strong oxidation-reduction quality and light sensitivity and thus can be used as medicines assisting in thermal therapy, meanwhile, the molecules have strong X-ray absorption capacity and thus can perform functions as auxiliary radiotherapy medicines, so that diagnosis and treatment of tumors can be realized simultaneously, integration of diagnosis and treatment can be realized, targeted treatment of tumors is enhanced, and the tumor treatment effect is improved.

The present invention relates to the fields of molecular medicine and targeted delivery of therapeutic or diagnostic agents to cells outside the vascular system and into the parenchymal tissue of organs within the body. More specifically, the present invention relates to the methods used to identify membrane receptors or transporters capable of carrying cargo specifically targeted to the parenchymal tissue of the brain and to in vivo enrichment methods for selecting peptides that are transported across the blood-brain barrier (“BBB”), or analogously, across other membrane containing organs or structures, such as liver, spleen, kidney and tumors.

The invention provides a neural stem cell specific gene delivery carrier and application thereof, and relates to the technical field of molecular pharmacology and molecular medicine. The delivery vector is a novel rAAV vector obtained by carrying out random gene mutation on the basis of a recombinant adeno-associated virus 9 and carrying out multiple rounds of in-vitro screening by taking neural stem cell spheres as a model. The amino acid sequence of the capsid protein of the delivery carrier is shown as SED ID NO: 1, the delivery carrier can efficiently deliver transgenic elements to neural stem cells in a targeted mode, compared with an rAAV9 carrier commonly used for transduction of a nervous system, the delivery carrier has the advantages that the transduction efficiency of the neural stem cells is remarkably improved, and the delivery carrier can be used for preparing drugs for diseases related to the nervous system.

The invention belongs to the technical field of biology, and relates to a composition and method for reprogramming human astrocytes into neurons or brain-like organs. The composition for efficiently reprogramming human astrocytes into neurons comprises a substance capable of realizing OCT4 overexpression, a substance knocking down a cell cycle regulation factor p53, and a small molecule drug capable of inducing human astrocytes to be reprogrammed into neurons, wherein the small molecule drug capable of inducing the human astrocytes to be reprogrammed into the neurons is selected from one or more of the following four small molecule drugs: CHIR99021, SB431542, RepSox or Y27632. Compared with the prior art, the composition and method have the following advantages: regulation and control of two genes are combined; a brand-new small molecular medicine composition capable of efficiently reprogramming human astrocytes into neurons and brain-like organs is obtained through a large amount of screening; and reliability of the system obtained through screening is verified on astrocytes differentiated from human embryonic stem cells H9 and astrocytes of para-tumor tissues of glioma patients.

The invention discloses application of a bladder urothelium carcinoma detection combined marker, and belongs to the technical field of molecular medicine. The bladder urothelium carcinoma detection combined marker comprises the following gene combinations: TERT, TP53, FGFR3, PIK3CA and ARID1A. According to the invention, it is found for the first time that a combination of five genes of TERT, TP53, FGFR3, PIK3CA and ARID1A can accurately diagnose bladder urothelial carcinoma. Compared with an original method, the method has the advantages that the five core gene detection combinations reduce the sequencing workload by 40 times, and good diagnostic performance is maintained.

The invention relates to a method and purpose of a lung cancer detection united marker, and belongs to the technical field of molecular medicines. The lung cancer detection united marker comprises gene combinations shown as follows: RB1, NKX2-1, CDK4, TP53 and MYC. The method disclosed by the invention has the following advantages that postoperative auxiliary chemotherapy or auxiliary target benefitting situation of EGFR sensitive mutation positive surgical non small-cell lung cancer can be distinguished, after single forecast factors are screened out by a precise statistics method, sensibility and specificity of forecast are improved through a marking model combining a plurality of gene markers, and the marker can be used for guiding selection of postoperative auxiliary treatment schemesof early-period and medium-period lung cancer.